Mergers & Acquisitions ·
Indivior completes merger with Supernus, creating $650M debt-funded CNS biopharma leader
SUPNSupernus, Inc.
Indivior Pharmaceuticals completed its previously announced business combination with Supernus Pharmaceuticals on November 2, 2026. The surviving entity was renamed Supernus, Inc., and former Indivior shareholders received a one-time special cash dividend of $1 billion funded by a new $650 million senior secured term loan facility from Citibank and existing cash. Former Supernus stockholders exchanged their shares for 1.5401 shares of the combined company's common stock, retaining approximately 43.5% ownership on a fully diluted basis. The combined entity operates as a diversified central nervous system (CNS) biopharmaceutical company with an 11-product portfolio.